Skip to content

Advertisement

BMC Research Notes

What do you think about BMC? Take part in

Open Access

Melanocortin agonists stimulate lipolysis in human adipose tissue explants but not in adipocytes

  • Cathrine Laustrup Møller1, 6,
  • Steen B. Pedersen4,
  • Bjørn Richelsen4,
  • Kilian W. Conde-Frieboes2,
  • Kirsten Raun3,
  • Kevin L. Grove5, 7 and
  • Birgitte Schjellerup Wulff1Email author
BMC Research Notes20158:559

https://doi.org/10.1186/s13104-015-1539-4

Received: 9 August 2015

Accepted: 2 October 2015

Published: 12 October 2015

Abstract

Background

The central melanocortin system is broadly involved in the regulation of mammalian nutrient utilization. However, the function of melanocortin receptors (MCRs) expressed directly in peripheral metabolic tissues is still unclear. The objective of this study was to investigate the lipolytic capacity of MC1-5R in differentiated adipocytes versus intact white adipose tissue.

Results

Non-selective MCR agonist α-MSH, MC5R-selective agonist PG-901 and MC4R-selective agonist LY2112688 significantly stimulated lipolysis in intact white adipose tissue, whereas stimulation of MCRs in differentiated adipocytes failed to do so. The lipolytic response of MC5R was decreased in intact human white adipose tissue when co-treating with β-adrenergic antagonist propranolol, suggesting that the effect may be dependent on neuronal innervation via noradrenalin release.

Conclusion

When developing an anti-obesity therapeutic drug with selective MC4R/MC5R properties, effects on lipolysis in white adipose tissue may be physiologically relevant.

Keywords

Melanocortin receptorMC5RMC4RLipolysisNEFAGlycerolPropranololWhite adipose tissue

Background

The melanocortin receptors (MCRs) are G-protein coupled receptors (family A), which are stimulated by endogenous proopiomelanocortin (POMC) derived agonists including ACTH and α-, β- and γ-MSH. The receptor system also contains melanocortin receptor-associated protein (MRAP) and MRAP2, as well as two antagonists, agouti-related peptide (AgRP) and agouti/agouti signaling protein (ASIP).

The melanocortin system has an essential function in the regulation of satiety, glucose homeostasis and energy expenditure [1, 2]. These effects are mainly mediated by MC4R expressed in the hypothalamus and the brainstem [3]. MC4R knockout mice have an increased lean body mass and fat mass, hyperphagia and disturbances in the metabolic response to overnutrition [3, 4]. Likewise, humans with MC4R mutations develop obesity [5], and in severe, early onset childhood obesity, the frequency of mutations in the MC4R locus causing decreased functionality is 4–6 % [6]. It has been shown that MC4R mRNA is expressed in autonomic control regions projecting to postganglionic neurons innervating peripheral metabolic tissues [3, 710]. Through sympathetic nerve innervation, CNS-MC4R has been shown to increase lipolysis in WAT [11, 12], insulin sensitivity in muscle [12, 13], thermogenesis in brown adipose tissue [10], fatty acid oxidation in liver [14] and decrease insulin release in pancreatic β-cells [15].

It is still rather unclear as to what extent peripherally expressed MCRs regulate metabolism. Notably, melanocortin peptides such as ACTH, β-lipotrophin, β-endorphin and α-MSH are released from the pituitary gland to the blood stream [1619], raising the possibility that there may be peripheral actions of melanocortins on metabolic systems. In addition, POMC expression has been identified in peripheral tissues such as the skin, testes, ovaries, placenta, adrenal glands, gastrointestinal tract, immune cells and tumors [20, 21]. The peripheral melanocortin system was initially examined for its effects on pigmentation and adrenal function mediated by MC1R and MC2R. MC1R action is primarily linked to melanocytes where α-MSH stimulation induces synthesis of the brown/black pigment eumelanin [22]. MC2R is expressed within the adrenal cortex where it regulates glucocorticoid production when activated by ACTH [23] and plays a pivotal role in the regulation of the hypothalamic–pituitary–adrenal axis. More recently, α-MSH has been shown to inhibit proliferation and adipogenesis in human preadipocytes mediated by MC1R, which is antagonized by agouti/ASIP [24]. Agouti/ASIP is a high affinity antagonist on MC1R and increased ectopic expression of this protein is associated phenotypically with yellow fur (mice), late onset obesity, hyperphagia, increased growth and non-insulin dependent diabetes [24]. Notably, ASIP mRNA is increased in subcutaneous WAT from type II diabetic patients and is suggested to be a paracrine hormone that may induce proliferation and adipogenesis [25]. MC1R mRNA expression is shown to be co-localized with macrophages in adipose tissue of obese subjects, suggesting an inflammatory function of this receptor [26]. Furthermore, α-MSH has been shown to decrease the expression and release of leptin from adipocytes as a part of a negative feedback loop to the CNS, which is antagonized by AgRP [27]. In rats, this effect is likely mediated by MC4R and MC5R [28]. Furthermore, a novel study by Panaro et al. shows that MC4R is expressed in cells of the gastrointestinal system and that MC4R agonist administration elevates plasma PYY and GLP-1 in mice [29].

MC5R is extensively distributed in the periphery [30, 31], and is reported to regulate sebaceous gland secretion [32] and fatty acid oxidation in skeletal muscle [33]. The melanocortin system has a well-established lipolytic effect in rodent adipose tissues [3437]. Studies in murine primary adipocytes and differentiated 3T3-L1 adipocytes show a direct lipolytic effect of MC2R and MC5R when stimulated by various endogenous and synthetic melanocortin agonists [35, 37, 38]. Moreover, an early study by Richter et al. showed a direct effect of α-MSH and ACTH on lipolysis in rabbit adipocytes [39]. However, it is unclear whether melanocortins have these actions in human adipose tissue. Expression of MC1R, MC4R and MC5R has been suggested in the adipose tissue of human obese subjects and these receptors may reflect an aspect of the pathophysiology of human obesity [26, 40, 41].

This study was undertaken to determine the lipolytic capacity of melanocortin receptors in differentiated human adipocytes versus intact adipose tissue. Initially, binding studies of selective- and non-selective MCR compounds were conducted on MC1-5R. We examined the possibility that MCR-mediated lipolysis is dependent on neuronal innervation via noradrenalin release in human adipose tissue.

Methods and procedures

Test compounds

α-MSH (Bachem), ACTH (Bachem), PG-901, LY2112688 (prepared in-house using standard peptide synthesis protocol); isoproterenol and propranolol were purchased from Sigma (Sigma-Aldrich Co. LLC).

Materials

Qiagen RNeasy mini kit was used for extraction of RNA from adipocytes. cDNA was synthesized using iScript™ (Biorad). Gene expression assays (ABI Life Technology) were used in PCR. PrimePCR DNA contamination assay from Biorad was used to determine genomic contamination of cDNA. Human subcutaneous adipocytes were purchased from Zenbio Inc. 199/EBSS Hyclone medium (Thermo Scientific) was used in incubation of human adipose tissue explants. NEFA-HR (2) kit from Wako and Glycerol colorimetric assay kit from CaymanChemicals was employed when measuring lipolysis.

Preparation of human WAT explants

Adipose tissue biopsies used for stimulation of lipolysis were taken from the subcutaneous abdominal region by needle aspiration as previously described [42]. The experimental group consisted of 6 non-diabetic females with a normal/preobese BMI (average BMI = 25.5). All biopsies were transported in sterile containers to the laboratory within 30 min after removal. The biopsies were washed repeatedly with isotonic saline and were used for subsequent culture.

Ethical consideration

Experiments with stimulation of human white adipose tissue explants at Aarhus University Hospital were approved by the local Ethics Committee, and the subjects provided written informed consent.

RNA extraction and cDNA synthesis

Qiagen RNeasy mini kit was used for extraction of RNA from adipocytes purchased at ZenBio. DNAse treatment was used in RNA extraction from adipocytes. The RNA was quantified measuring absorbance at 260 nm by Nanodrop and the purity of the RNA was indicated by a 260/280 ratio of 1.8 or higher to ensure no protein contamination. Finally, the integrity of the RNA was checked by visual inspection of the two ribosomal RNAs 18S and 28S on an agarose gel. iScript™ cDNA synthesis reactions were incubated 5 min at 25 °C, 30 min at 42 °C and 5 min at 85 °C. We found no genomic contamination of cDNA (using Biorad DNA contamination assay).

PCR

In standard PCR, RNA was extracted from adipocytes isolated from 3 obese males (purchased from Zenbio) and pooled (cDNA 1:10 from 1 μg RNA, 45 cycles). Each reaction was prepared using 13 μl of Platinum PCR supermix (Invitrogen), 5 μl of gene expression assay and 2 μl of cDNA. The gene expression assays used were: hsMC1R (NM_002386.3): Hs00267168-S1; hsMC2R (NM_000529.2): Hs003000820-S1; hsMC3R (NM_019888.3): Hs01562847-S1; hsMC4R (NM_005912.2): Hs00271877_S1; hsMC5R (NM_005913.1): Hs00271882_S1; hsGAPDH (NM_002046.4): Hs02758991_g1.

Binding studies

The human MC1R, MC3R, MC4R and MC5R were cloned by PCR and subcloned into the pcDNA3 expression vector, as previously described by Conde-Frieboes et al. [43]. Cells stably expressing the human MCRs were generated by transfecting the expression vector into BHK570 cells (ATTC) and using 1 mg/mL G418 to select for stable clones. The stable cell lines were cultured in DMEM with glutamax, 10 % FCS, 1 % pen/strep, and 1 mg/mL G418 at 37 °C and 5 % CO2. Binding affinities were obtained in vitro using 125I-NDP-α-MSH binding to membranes from recombinant BHK570 cells expressing the relevant human melanocortin receptor. Test compounds were dissolved to a 4 mM concentration in DMSO and diluted in a receptor specific binding buffer. A fixed concentration of 125I-NDP-α-MSH and varying concentrations (10 μM–1 pM) of non-labelled competing test compound were added to the cells. A filtration system was employed to separate bound from unbound radioligand.

NEFA and glycerol release in differentiated human adipocytes and WAT explants

Induction of NEFA and glycerol release in adipocytes and intact adipose tissue explants was used as a measure of lipolysis with β-adrenergic agonist isoproterenol as a positive control as previously described [35]. When using propranolol, 10 μM was used as final concentration. 250 mg of human adipose tissue was placed in 15 mL tubes, immediately covered with 2.5 mL of preheated (37 °C) hyclone media and preincubated for 24 h. After 24 h, the media was replenished and explants were stimulated with the indicated melanocortin peptide for 3 h before harvesting the supernatant for NEFA and glycerol analysis. In house testing has shown no indications of hypoxia when stimulating explants (data not shown). All test compounds were dissolved to 4 mM in DMSO (highest DMSO concentration of 0.25 % in the assay) and diluted in DPBS buffer + 2 % bovine serum albumin (BSA). Human subcutaneous adipocytes purchased from Zenbio Inc., were used in stimulation of lipolysis (n = 4). These adipocytes have been isolated from obese males. When receiving the cells (and partially during transportation), the cells was differentiated from a pre-state to a mature state before the cells are used for experiments. The cells were handled according to the description from ZenBio Inc. Two hours was chosen as the optimal incubation time span for primary adipocytes, based on similar experiments in other species [35]. The release of NEFA proved to be a reproducible measure of lipolysis, though potential re-esterification of NEFAs would underestimate the degree of MCR mediated lipolysis. Indeed, a potent release of NEFA was stimulated by positive control isoproterenol in both adipocytes and intact adipose tissue explants. Measures of melanocortin-stimulated glycerol release were added in explant lipolysis studies.

Data analysis and statistics

Data from the NEFA and the glycerol assay were obtained using the protocol supplied by the manufactures. Released NEFAs were analyzed in Graphpad Prism and one-tailed t test was used to calculate statistical significance between 2 groups (*p < 0.05, **p < 0.01, ***p < 0.001, no * indicates insignificance). Ki values in bindings studies were calculated as Ki = IC50/1 + [radioligand]/Kd. Data from binding studies was analyzed in Graphpad Prism.

Results

Binding data of known melanocortin analogues to MC1R, MC3R, MC4R and MC5R

In order to assess MCR agonist specificity, competition binding curves of α-MSH, ACTH, PG-901 and LY2112688 were obtained using cells overexpressing the human MCRs (Table 1). MC2R is acknowledged to be activated only by ACTH [23], and for this reason, binding studies were not performed on this receptor. Our binding data support that remaining MCRs bind ACTH with relatively high affinities (MC1R > MC4R > MC3R > MC5R), which is also consistent with previous studies [44]. Results obtained support present literature on human MCRs, stating that α-MSH is a non-selective agonist that binds to all MCRs [45]. LY2112688 has previously been studied by Greenfield et al., who found that the agonist was highly selective for MC4R, having an increased affinity for MC4R over MC1R of a factor more than 30 and over MC3R of a factor of more than 100 [46]. We support that LY2112688 is selective for human MC4R (Ki = 0.13 ± 0.01), but we find the binding rank order to be MC4R > MC3R > MC1R. Notably, the affinity of LY2112688 for MC1R is 165 ± 51 nM, which is in the range of concentrations used in lipolysis assay. In the literature, PG-901 binds MC5R (agonist), as well as MC3R and MC4R (antagonist) with high affinity [47], which is consistent with our studies.
Table 1

Binding (Ki) of melanocortin peptides to human MCRs: Indicated values are an average from repeated independent experiments (±SEM)

Test compound

hMC1R

hMC3R

hMC4R

hMC5R

K i (nM)

K i (nM)

K i (nM)

K i (nM)

LY2112688

165 ± 51 (3)

74 ± 27 (3)

0.13 ± 0.01(3)

1713 ± 686 (3)

PG-901

2700 ± 153 (3)

11 ± 0.5 (4)

0.08 ± 0.01 (3)

1.7 ± 0.6 (4)

α-MSH

1.5 ± 0.4 (18)

46 ± 5 (9)

10.16 ± 3.4 (3)

150 ± 30 (7)

ACTH

0.09 ± 0.01 (3)

11.1 ± 1.5 (5)

1.2 ± 0.2 (3)

46 ± 9.5 (5)

Ki values were calculated from competition binding curves of α-MSH, PG-901 and LY2112688 obtained on cells expressing MC1, 3, 4 and 5R as described using a fixed concentration of I125-NDP-α-MSH and increasing amounts of non-labelled competing peptides (1 pM–10 μM)

NEFA release in subcutaneous explants from human white adipose tissue

To examine the function of MCRs in human adipose tissue, we investigated the ability of MCR agonists to stimulate lipolysis in intact explants (Fig. 1). Isoproterenol, which is known to stimulate release of NEFA in human WAT through activation of the β-adrenergic receptors, was used as a positive control. Indeed, the release of NEFA was increased by 114 % using 100 nM isoproterenol compared to vehicle (Fig. 1a). Furthermore, 100 nM α-MSH, MC4R-selective agonist LY2112688 and MC5R-selective agonist PG-901 stimulated a low, though significant, release of NEFA (32, 46 and 38 % increase compared to the vehicle). PG-901 and LY2112688 also stimulated release of glycerol. Compared to isoproterenol, α-MSH, LY2112688 and PG-901 stimulated lipolysis with a relatively lower Emax. Notably, ACTH failed to stimulate NEFA and glycerol release in human WAT explants (Fig. 1a, b). Binding results obtained in this study support that LY2112688 has high affinity (Ki = 0.13 ± 0.01 nM) for the human MC4R and lower affinity for other human melanocortin receptors. However, as LY2112688 bind to MC1R with a Ki = 165 ± 51 nM, the LY2112688-stimulation of lipolysis may partially be mediated by MC1R considering the concentration used.
Fig. 1

Non-esterified fatty acid (NEFA) and glycerol release in intact adipose tissue explants from human. a NEFA release was measured after stimulation with increasing doses of isoproterenol or the indicated melanocortin peptide (100 nM–10 μM) in subcutaneous explants from non-obese females. The mean of 6 independent experiments (α-MSH, 3 independent experiments) in triplicate wells (mean ± SEM) are shown. b Glycerol release was measured after stimulation with increasing doses of isoproterenol or the indicated melanocortin peptide (100 nM–10 μM) in subcutaneous explants from non-obese females. The mean of 2 independent experiments in triplicate wells (mean ± SEM) are shown. Unpaired one-tailed t test was used to calculate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle)

MCRs have no lipolytic effect in differentiated adipocytes from obese human subjects

We investigated the ability of the MCR agonists to stimulate lipolysis in subcutaneous adipocytes from obese males (purchased from Zenbio). While isoproterenol induced a potent release of NEFA in human subcutaneous adipocytes (EC50 = 1.64 ± 0.34 nM) α-MSH, ACTH, PG-901 and LY2112688 all failed to stimulate NEFA release (Fig. 2). We also stimulated visceral adipocytes with the same results as in Fig. 2 (data not shown). Standard PCR showed that the expression of MC3R and MC4R mRNA is low in subcutaneous adipocytes in the conditions used, whereas the expression of MC1R, MC2R and MC5R is higher (Fig. 2).
Fig. 2

Non-esterified fatty acid (NEFA) release in human subcutaneous adipocytes: a Adipocytes purchased from ZenBio were incubated with increasing concentrations (1 pM–10 μM) of positive control isoproterenol (EC50 = 1.46 ± 0.34 nM), ACTH, α-MSH, PG-901 and LY2112688 (n = 4). NEFA release was measured as described. Experiments were carried out in duplicates. Data are shown as average values ± SEM. b MC1-5R and GAPDH mRNA expression was measured in same adipocytes (n = 3 pooled). cDNA was synthesized and mRNA levels determined by standard PCR (cDNA 1:10 from 1 μg RNA, 45 cycles)

The partial lipolytic effect of MC5R in explants is dependent on postsynaptic innervation

Since we only observed a lipolytic effect in intact adipose tissue and not in adipocytes, we examined whether MCR-mediated lipolysis involves neuronal interaction. Hence, we co-incubated PG-901 and LY2112688 with β-adrenergic antagonist propranolol in intact adipose tissue (Fig. 3). Use of propranolol significantly decreased the release of NEFA stimulated by isoproterenol and MC5R selective agonist PG-901. This result suggests that the lipolytic effect of MC5R may be mediated by noradrenalin released from postsynaptic nerve fibers innervating the adipose tissue. Use of propranolol did not significantly decrease the release of NEFA stimulated by MC4R-selective agonist LY2112688, although there is a clear trend.
Fig. 3

Non-esterified fatty acid (NEFA) release in human white adipose tissue (WAT) explants ± propranolol: NEFA was measured after stimulation with indicated melanocortin peptide analogue (100 nM–10 μM) in subcutaneous explants from female human ± 10 μM β-adrenergic antagonist propranolol (PRO). The mean ± SEM of 3 independent experiments in triplicate wells are shown. Unpaired one-tailed t test was used to calculate statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001 vs. vehicle; +p < 0.05, ++p < 0.01, +++p < 0.001 vs. −7)

Discussion

Melanocortin receptors are important central regulators of energy metabolism and feeding behavior. These receptors also have a direct lipolytic effect in rodent [35, 37, 38] and rabbit [39] adipose tissues. The storage and release of lipids in adipose tissue is a highly regulated process, which play an essential role in whole body homeostasis. A systemic abundance of both endogenous melanocortin agonists and antagonists have been established [1, 18, 48] and MCRs are expressed in peripheral tissues relevant for lipid metabolism. Hoch et al. established MC1R mRNA expression in adipose tissue [26], Chhajlani et al. identified MC1R and MC5R in omental adipose tissue [41] and Chagnon et al. linked MC4R and MC5R with an obese-related phenotype [40]. The presence of a peripheral melanocortin system in adipose tissue is supported by results from this study.

In this study, we show that α-MSH, MC5R selective agonist PG-901 and MC4R selective agonist LY2112688 significantly stimulate release of NEFA in intact adipose tissue. Notably, as LY2112688 bind to MC1R with a Ki = 165 ± 51 nM, the LY2112688-stimulation of lipolysis may partially be mediated by MC1R considering the concentration used. A recent study by Rodrigeus et al. showed that α-MSH-stimulated MC5R regulates both lipolysis and re-esterification in murine 3T3-L1 cells, though the global effect is a decrease in adipocyte fat mass [49]. This may be relevant in terms of the MC5R-mediated lipolysis seen is this study, as some of the released free fatty acids (FFAs) may be re-esterified and taken up by the adipocyte again. However, as PG-901 and LY2112688 also stimulated release of glycerol there seems to be a persistent lipolytic effect of these compounds.

The lipolytic response of PG-901 was significantly decreased when using β-adrenergic antagonist propranolol, suggesting that the effect may be dependent on neuronal innervation via noradrenalin release (Fig. 4). Propranolol is a non-selective β-adrenergic antagonist that is used as a golden standard for inhibition of neuronal innervation. However, it should be taken into account, that there may be downstream MCR mechanisms of propranolol that are unknown, which is a precaution using this antagonist. Depleting the explants with reserpine before stimulation could add additional confidence to the result of propranolol. Centrally expressed MC4R in the hypothalamus and the brainstem has in several studies been shown to regulate peripheral metabolism through sympathetic nerve innervation. Through innervation, CNS-MC4R increases lipolysis in WAT [11, 12], insulin sensitivity in muscle [12, 13], thermogenesis in brown adipose tissue (BAT) [10], fatty acid oxidation in liver [14] and decreases insulin release in pancreatic β-cells [15] as mentioned previously. Likewise, Wellhöner et al. showed that intranasal MSH/ACTH(4-10) administration increased glycerol concentrations in WAT, presumably mediated by centrally expressed MC4R [50]. However, the mode of action suggested in the present study is not a CNS-MCR regulated pathway. Instead, we suggest that peripherally expressed MC5R co-localized with post-synaptic neurons directly in adipose tissue regulate low grade lipolysis. Notably, the central and peripheral regulation of MCR-mediated lipolysis may not exclude each other. α-MSH has been shown to inhibit proliferation and adipogenesis in human preadipocytes mediated by MC1R, which is antagonized by agouti [24]. Considering the above, a lipolytic capacity of α-MSH in human adipose tissue seems plausible. If stimulation of MC5R/MC4R in adipose tissue leads to increased levels of plasma FFA and glycerol, these lipids may likely be absorbed and metabolized in the liver. This may lead to increased hepatic lipid deposition and potentially hepatic insulin resistance. However, if energy expenditure simultaneously is increased by melanocortins these lipids may also serve as energy substrates to be utilized in muscle. Notably, An et al. has shown that MC5R mediates α-MSH-stimulated fatty acid oxidation in muscle tissue [33]. Additional studies are needed to determine where in fact the released lipids are absorbed and metabolized.
Fig. 4

An overview of melanocortin receptor (MCR)-mediated lipolysis in intact human white adipose tissue (WAT). It is hypothesised that MC4/5R mRNA is expressed on nerve terminals innervating WAT. α-MSH from the circulation or from ectopic production binds to MC4/5R, which increase the release of noradrenalin from the terminal. Stimulated β1–3-adrenergic receptors couple to Gαs and downstream adenylate cyclase leading to increased intracellular cAMP and activation of protein kinase A (PKA). The induction of lipolysis mediated by MC4R and MC5R is suggested to be dependent on neuronal innervation via noradrenalin release, since co-incubation of propranolol (non-selective β-adrenergic receptor antagonist) inhibits NEFA release

We find no lipolytic capacity of ACTH in either adipocytes or intact human adipose tissue, which is supported by other studies [51, 52]. ACTH is a larger peptide than both α-MSH and the synthetic melanocortin compounds used in this study. It is possible that the lack of lipolytic response ex vivo observed when stimulating with ACTH is due to the size of the peptide. Opposing results have been reported by Xue et al. who stimulated lipolysis using ACTH in adipocytes isolated from subcutaneous adipose tissue of non-diabetic human [53].

We, and others, have previously shown that the melanocortin system is involved in peripheral regulation of adipocyte metabolism in mice and has direct lipolytic capacity in addition to central regulation. Indeed, ACTH and α-MSH were reported to have a lipolytic capacity in primary mouse adipocytes, which is mediated by MC2R and MC5R [35, 37, 38]. This result was not found in human adipocytes, which suggests essential species differences in the melanocortin system between mice and humans. The lack of lipolytic response seen in adipocytes is supported by previous studies by Hoch et al. [52]. Hoch et al. induced a weak cAMP response using NDP-α-MSH in mesenchymal stem cell-derived adipocytes. However, they did not find an effect on lipolysis in either these cells or in intact adipose tissue explants [52].

Further studies are needed in order to establish the relevance of the melanocortin receptor accessory proteins, MRAP and MRAP2, in intact adipose tissue versus adipocytes. Studies have shown that all MCRs may employ an accessory protein, which modulates the functionality of the receptor [54]. It may be that MRAP/MRAP2 mRNA levels are not equally expressed in the stroma vascular fraction (SVF) and in isolated adipocytes.

Collectively, the Emax induced by melanocortin peptides in intact adipose tissue explants is small compared to isoproterenol. It is possible that the melanocortin system has other functions in adipose tissue than induction of lipolysis. The SVF of adipose tissue consists of cells such as preadipocytes, mesenchymal stem cells, several types of inflammatory cells, as well as nerve fibers and blood vessels. α-MSH inhibits TNF-α-induced NF-κB in immune cells [55], as well as in a subset of other human cells such as melanocytes, fibroblasts, keratinocytes, endothelial cells and Schwann cells of the peripheral nervous system [56]. Suppression of NF-κB potentially controls the expression of 150 genes including cytokines for which reason the involvement of the melanocortins in inflammation is potentially profound [56]. It has been shown that the inflammatory effects of the melanocortin system are regulated through mainly MC1R and MC3R [26, 56]. Hence the primary function of MCRs in human adipose tissue may be inflammatory rather than lipolytic [52].

We find that various selective and non-selective melanocortin peptides significantly induce low-grade lipolysis in intact human adipose tissue. The physiological relevance of these receptors in terms of human adipose tissue lipolysis is probably minimal. The plasma level of circulating endogenous α-MSH and ACTH is on average reported to be 11 pmol/l (~0.011 nM) and 14.5 pmol/l (~0.015 nM) [27]. These concentrations are not compatible with the concentration of endogenous and synthetic melanocortin receptor ligands used in this study. However, even the physiological concentration of endogenous α-MSH circulating in the human body is below the EC50 values for the peripheral MCRs [57]. Does circulating α-MSH have any physiological relevance for adipose tissue metabolism? In terms of circulating endogenous melanocortin peptides the answer is probably no. However, in terms of developing an anti-obesity therapeutic drug with selective MC4R/MC5R properties directed against the effects on satiety and energy expenditure, the answer may be yes. In addition, paracrine POMC-secretion/ectopic POMC-production could increase the concentration and exposure of ACTH and α-MSH to MCRs in peripheral tissues such as white adipose tissue.

Conclusion

Selective and non-selective melanocortin peptides significantly induce low-grade lipolysis in intact human adipose tissue but not in adipocytes. The lipolytic response of MC5R was decreased in intact human white adipose tissue when co-treating with β-adrenergic antagonist propranolol, suggesting that the effect may be dependent on neuronal innervation via noradrenalin release. These effects may be physiologically relevant, when developing an anti-obesity therapeutic drug with selective MC4R/MC5R properties.

Abbreviations

AgRP: 

Agouti-related peptide

ASIP: 

Agouti signaling protein

BMI: 

Body mass index

FFA: 

Free fatty acids

MCR: 

Melanocortin receptor

MRAP: 

Melanocortin receptor-associated protein

NEFA: 

Non-esterified fatty acid

POMC: 

Proopiomelanocortin

PRO: 

Propranolol

SVF: 

Stroma vascular fraction

WAT: 

White adipose tissue

Declarations

Authors’ contribution

Study design, data analysis and data interpretation was carried out by CLM, BSW, KLG and KR. CLM carried out NEFA release and PCR experiments, the literature search, generation of figures and writing of the manuscript. Stimulations in human adipose tissue explants were carried out at the Department of Endocrinology MEA, Aarhus University Hospital, supervised by SBP and BR. KWC carried out peptide synthesis of the used compounds. All authors were involved in writing the paper. All authors read and approved the final manuscript.

Acknowledgements

The technical assistance of Lenette Pedersen, Pia Hornbek and Marianne Lambert Jacobsen has been greatly appreciated.

Competing interests

KR, KWC, KLG and BSW (corresponding author) are presently employees at Novo Nordisk A/S. CLM was an employee at Novo Nordisk A/S at the time of the study. CLM was funded by Novo Nordisk A/S and The Danish Ministry of Higher Education and Science at the time of the study. KLG was at the time of the study on the Novo Nordisk Advisory Board and a consultant for Sanofi and Ember Therapeutics. Salary support for KLG from PO1 OD0011092.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Diabetes and Obesity Biology, Novo Nordisk A/S
(2)
Protein and Peptide Chemistry 3, Novo Nordisk A/S
(3)
Type 2 Diabetes, Novo Nordisk A/S
(4)
Department of Endocrinology MEA, Aarhus University Hospital
(5)
Diabetes, Obesity and Metabolism, Oregon National Primate Research Centre, Oregon Health & Science University
(6)
Steno Diabetes Center
(7)
Obesity Research, Novo Nordisk A/S

References

  1. Yaswen L, et al. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med. 1999;5(9):1066–70.View ArticlePubMedGoogle Scholar
  2. Cheung CC, Clifton DK, Steiner RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology. 1997;138(10):4489–92.View ArticlePubMedGoogle Scholar
  3. Mountjoy KG, et al. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol. 1994;8(10):1298–308.PubMedGoogle Scholar
  4. Huszar D, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997;88(1):131–41.View ArticlePubMedGoogle Scholar
  5. Krude H, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155–7.View ArticlePubMedGoogle Scholar
  6. Farooqi IS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348(12):1085–95.View ArticlePubMedGoogle Scholar
  7. Kishi T, et al. Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J Comp Neurol. 2003;457(3):213–35.View ArticlePubMedGoogle Scholar
  8. Williams DL, et al. Brainstem melanocortin 3/4 receptor stimulation increases uncoupling protein gene expression in brown fat. Endocrinology. 2003;144(11):4692–7.View ArticlePubMedGoogle Scholar
  9. Voss-Andreae A, et al. Role of the central melanocortin circuitry in adaptive thermogenesis of brown adipose tissue. Endocrinology. 2007;148(4):1550–60.View ArticlePubMedGoogle Scholar
  10. Song CK, et al. Melanocortin-4 receptor mRNA is expressed in sympathetic nervous system outflow neurons to white adipose tissue. Am J Physiol Regul Integr Comp Physiol. 2005;289(5):R1467–76.View ArticlePubMedGoogle Scholar
  11. Brito MN, et al. Differential activation of the sympathetic innervation of adipose tissues by melanocortin receptor stimulation. Endocrinology. 2007;148(11):5339–47.View ArticlePubMedGoogle Scholar
  12. Nogueiras R, et al. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest. 2007;117(11):3475–88.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Rossi J, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab. 2011;13(2):195–204.PubMed CentralView ArticlePubMedGoogle Scholar
  14. Lam TK, et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis. Nat Med. 2005;11(3):320–7.View ArticlePubMedGoogle Scholar
  15. Obici S, et al. Central melanocortin receptors regulate insulin action. J Clin Invest. 2001;108(7):1079–85.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Pritchard LE, White A. Neuropeptide processing and its impact on melanocortin pathways. Endocrinology. 2007;148(9):4201–7.View ArticlePubMedGoogle Scholar
  17. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005;8(5):571–8.View ArticlePubMedGoogle Scholar
  18. Roth CL, et al. Changes of peripheral alpha-melanocyte-stimulating hormone in childhood obesity. Metabolism. 2010;59(2):186–94.View ArticlePubMedGoogle Scholar
  19. Mains RE, Eipper BA. Synthesis and secretion of corticotropins, melanotropins, and endorphins by rat intermediate pituitary cells. J Biol Chem. 1979;254(16):7885–94.PubMedGoogle Scholar
  20. Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27(7):736–49.View ArticlePubMedGoogle Scholar
  21. Wikberg JE, et al. New aspects on the melanocortins and their receptors. Pharmacol Res. 2000;42(5):393–420.View ArticlePubMedGoogle Scholar
  22. Abdel-Malek Z, et al. The melanocortin-1 receptor and human pigmentation. Ann N Y Acad Sci. 1999;885:117–33.View ArticlePubMedGoogle Scholar
  23. Baumann JB, et al. Steroidogenic activity of highly potent melanotropic peptides in the adrenal cortex of the rat. Acta Endocrinol (Copenh). 1986;113(3):396–402.Google Scholar
  24. Smith SR, et al. Agouti expression in human adipose tissue: functional consequences and increased expression in type 2 diabetes. Diabetes. 2003;52(12):2914–22.View ArticlePubMedGoogle Scholar
  25. Voisey J, et al. Body mass index-related human adipocyte agouti expression is sex-specific but not depot-specific. Obes Res. 2002;10(6):447–52.View ArticlePubMedGoogle Scholar
  26. Hoch M, et al. Expression and localization of melanocortin-1 receptor in human adipose tissues of severely obese patients. Obesity. 2007;15(1):40–9.View ArticlePubMedGoogle Scholar
  27. Hoggard N, et al. Regulation of adipose tissue leptin secretion by alpha-melanocyte-stimulating hormone and agouti-related protein: further evidence of an interaction between leptin and the melanocortin signalling system. J Mol Endocrinol. 2004;32(1):145–53.View ArticlePubMedGoogle Scholar
  28. Mountjoy KG. Functions for pro-opiomelanocortin-derived peptides in obesity and diabetes. Biochem J. 2010;428(3):305–24.View ArticlePubMedGoogle Scholar
  29. Panaro BL, et al. The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo. Cell Metab. 2014;20(6):1018–29.View ArticlePubMedGoogle Scholar
  30. Bednarek MA, et al. Potent and selective peptide agonists of alpha-melanocyte stimulating hormone (alphaMSH) action at human melanocortin receptor 5; their synthesis and biological evaluation in vitro. Chem Biol Drug Des. 2007;69(5):350–5.View ArticlePubMedGoogle Scholar
  31. Fathi Z, Iben LG, Parker EM. Cloning, expression, and tissue distribution of a fifth melanocortin receptor subtype. Neurochem Res. 1995;20(1):107–13.View ArticlePubMedGoogle Scholar
  32. van der Kraan M, et al. Expression of melanocortin-5 receptor in secretory epithelia supports a functional role in exocrine and endocrine glands. Endocrinology. 1998;139(5):2348–55.PubMedGoogle Scholar
  33. An JJ, et al. Peripheral effect of alpha-melanocyte-stimulating hormone on fatty acid oxidation in skeletal muscle. J Biol Chem. 2007;282(5):2862–70.View ArticlePubMedGoogle Scholar
  34. Boston BA. The role of melanocortins in adipocyte function. Ann N Y Acad Sci. 1999;885:75–84.View ArticlePubMedGoogle Scholar
  35. Moller CL, et al. Characterization of murine melanocortin receptors mediating adipocyte lipolysis and examination of signalling pathways involved. Mol Cell Endocrinol. 2011;341(1–2):9–17.View ArticlePubMedGoogle Scholar
  36. Spirovski MZ, et al. Effect of ACTH on lipolysis in adipose tissue of normal and adrenalectomized rats in vivo. Am J Physiol. 1975;228(2):382–5.PubMedGoogle Scholar
  37. Boston BA, Cone RD. Characterization of melanocortin receptor subtype expression in murine adipose tissues and in the 3T3-L1 cell line. Endocrinology. 1996;137(5):2043–50.PubMedGoogle Scholar
  38. Cho KJ, et al. Signaling pathways implicated in alpha-melanocyte stimulating hormone-induced lipolysis in 3T3-L1 adipocytes. J Cell Biochem. 2005;96(4):869–78.View ArticlePubMedGoogle Scholar
  39. Richter WO, Schwandt P. Lipolytic potency of proopiomelanocorticotropin peptides in vitro. Neuropeptides. 1987;9(1):59–74.View ArticlePubMedGoogle Scholar
  40. Chagnon YC, et al. Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Quebec Family Study. Mol Med. 1997;3(10):663–73.PubMed CentralPubMedGoogle Scholar
  41. Chhajlani V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem Mol Biol Int. 1996;38(1):73–80.PubMedGoogle Scholar
  42. Pedersen SB, et al. Relationship between sex hormones, body composition and metabolic risk parameters in premenopausal women. Eur J Endocrinol. 1995;133(2):200–6.View ArticlePubMedGoogle Scholar
  43. Conde-Frieboes K, et al. Identification and in vivo and in vitro characterization of long acting and melanocortin 4 receptor (MC4-R) selective alpha-melanocyte-stimulating hormone (alpha-MSH) analogues. J Med Chem. 2012;55(5):1969–77.View ArticlePubMedGoogle Scholar
  44. Gantz I, Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab. 2003;284(3):E468–74.View ArticlePubMedGoogle Scholar
  45. Haskell-Luevano C, et al. Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors. J Med Chem. 1997;40(11):1738–48.View ArticlePubMedGoogle Scholar
  46. Greenfield JR, et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med. 2009;360(1):44–52.View ArticlePubMedGoogle Scholar
  47. Grieco P, et al. Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6. Biochem Biophys Res Commun. 2002;292(4):1075–80.View ArticlePubMedGoogle Scholar
  48. Shishioh-Ikejima N, et al. The increase of alpha-melanocyte-stimulating hormone in the plasma of chronic fatigue syndrome patients. BMC Neurol. 2010;10:73.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Rodrigues AR, Almeida H, Gouveia AM. Alpha-MSH signalling via melanocortin 5 receptor promotes lipolysis and impairs re-esterification in adipocytes. Biochim Biophys Acta. 2013;1831(7):1267–75.View ArticlePubMedGoogle Scholar
  50. Wellhoner P, et al. Intranasal application of the melanocortin 4 receptor agonist MSH/ACTH(4–10) in humans causes lipolysis in white adipose tissue. Int J Obes (Lond). 2012;36(5):703–8.View ArticleGoogle Scholar
  51. Kiwaki K, Levine JA. Differential effects of adrenocorticotropic hormone on human and mouse adipose tissue. J Comp Physiol B. 2003;173(8):675–8.View ArticlePubMedGoogle Scholar
  52. Hoch M, et al. Weak functional coupling of the melanocortin-1 receptor expressed in human adipocytes. J Recept Signal Transduct Res. 2008;28(5):485–504.View ArticlePubMedGoogle Scholar
  53. Xue B, et al. The agouti gene product inhibits lipolysis in human adipocytes via a Ca2+-dependent mechanism. FASEB J. 1998;12(13):1391–6.PubMedGoogle Scholar
  54. Chan LF, et al. MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor family. Proc Natl Acad Sci USA. 2009;106(15):6146–51.PubMed CentralView ArticlePubMedGoogle Scholar
  55. Manna SK, Aggarwal BB. Alpha-melanocyte-stimulating hormone inhibits the nuclear transcription factor NF-kappa B activation induced by various inflammatory agents. J Immunol. 1998;161(6):2873–80.PubMedGoogle Scholar
  56. Eves PC, Haycock JW. Melanocortin signalling mechanisms. Adv Exp Med Biol. 2010;681:19–28.View ArticlePubMedGoogle Scholar
  57. Hoggard N, et al. Plasma concentrations of alpha-MSH, AgRP and leptin in lean and obese men and their relationship to differing states of energy balance perturbation. Clin Endocrinol (Oxf). 2004;61(1):31–9.View ArticleGoogle Scholar

Copyright

© Møller et al. 2015

Advertisement